The Dermatology Digest

MARCH 10, 2025

improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

MARCH 8, 2025

The research was presented as a late-breaker at the 2025American Academy of Dermatology(AAD) Annual Meeting inOrlando, FL. The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% The overall safety profile of ruxolitinib cream 1.5%

Safety 36

Safety Clinic Therapy Dermatology 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Krystal Briglia, L+A Medical + Wellness Editor Dr. Krystal Briglia of Triada Integrative Medicine + Wellness is a board-certified nurse practitioner specializing in aesthetic dermatology, integrative medicine, and wellness. Journal of Dermatological Science. Journal of the American Academy of Dermatology. Dermatologic Therapy.

Chemical Peels 52

Chemical Peels Vitamin C Hyperpigmentation Microneedling 52

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up. 75mg: 40.6% 75mg: 42.3%

Safety 36

Safety Document Clinic Therapy 36

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients. The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

FEBRUARY 25, 2025

This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported. FDA Approves IND for Ruxoprubart in DM appeared first on The Dermatology Digest. The post U.S.

Safety 36

Safety Therapy Clinic Dermatology 36

The Dermatology Digest

MARCH 17, 2025

The multi-center, randomized, double-blind, placebo-controlled, proof-of-concept trial is designed to evaluate the safety and efficacy of EVO301 in approximately 60 adult patients with moderate-to-severe AD. EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

Dermatology Times

APRIL 4, 2025

Aaron Farberg, MD, discuss how to educate parents about the potential adverse effects of a new therapy while also reassuring them about its overall safety profile by providing clear, evidence-based information and emphasizing the rigorous testing and monitoring processes.

Safety 36

Safety Education Therapy 36

Dermatology Times

MARCH 28, 2025

Lisa Swanson, MD, FAAD, discusses how to balance the need for effective control of Alzheimer's disease symptoms with concerns about long-term safety, particularly when introducing new therapies.

Safety 36

Safety Therapy 36

The Dermatology Digest

MARCH 3, 2025

We are excited to be able to provide DEB patients with the first treatment that corrects the genetic defect and makes a true difference in their lives, says Cristina Has, MD, Professor and Head of the Genodermatoses Clinic in the Department of Dermatology at the University of Freiburg in Germany, in a news release.

Therapy 36

Therapy Clinic Hospital Dermatology 36

The Dermatology Digest

JULY 1, 2024

PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

Portfolios 74

Portfolios Safety Clinic Injections 74

Dermatology Times

JUNE 4, 2024

This week’s collection of the latest dermatologic studies includes the use of digital communication for patients with hidradenitis suppurativa (HS), rituximab for pediatric patients with pemphigus, a case report of primary oral extramammary Paget disease, and the efficacy and safety of LAight therapy for HS.

Safety 69

Safety Therapy Dermatology 69

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Training Clinic 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Training Clinic 78

The Dermatology Digest

MARCH 18, 2025

has completed enrollment in its Phase 3 clinical trial evaluating aminolevulinic acid hydrochloride (Ameluz) with photodynamic therapy (PDT) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. Biofrontera Inc.

Treatments 36

Treatments Dermatology Safety Therapy 36

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4%

Dermatitis 36

Dermatitis Safety Office Eczema 36

Dermatology Times

OCTOBER 4, 2024

While researchers found both therapies effective in long-term use, they stated secukinumab showed quicker improvements in QoL.

Therapy 45

Therapy Safety 45

The Dermatology Digest

OCTOBER 30, 2024

Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

Sun Protection 36

Sun Protection Dermatology Innovations Safety 36

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

AUGUST 20, 2024

Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. The adverse events were consistent with the known safety profile of Otezla in adult patients.

Safety 74

Safety Injections Therapy Treatments 74

Dermatology Times

JULY 4, 2024

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Safety 36

Safety Therapy Treatments 36

The Dermatology Digest

NOVEMBER 6, 2024

This could help doctors better predict which therapies will work best for each patient. He will test ONT01, which has shown promising results in mouse models, in a phase 1b trial to assess its safety in people with lupus. This trial could open the door to a new class of treatments that target lupus at the molecular level.

Hospital 36

Hospital Therapy Management Networking 36

The Dermatology Digest

FEBRUARY 10, 2025

The submission will be supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients. The post INmune Bio to Submit FDA BLA for CORDStrom in RDEB appeared first on The Dermatology Digest.

Hospital 36

Hospital Sustainability Therapy Marketing 36

US Dermatologt Partners

JUNE 1, 2024

In the ever-evolving landscape of psoriasis treatment, oral therapies continue to play a crucial role. 1 In an interview with Dermatology Times, Lockshin explained how far we have come in oral treatment options for psoriasis, the future outlook, and patient populations that benefit most from orals. 7 Oral Options vs.

Therapy 41

Therapy Injections Safety Management 41

The Dermatology Digest

JANUARY 29, 2025

The topical pan-Janus kinase (JAK) inhibitor demonstrated superior treatment effects, quality of life improvements, and a more favorable safety profile compared to oral alitretinoin over 24 weeks. A systemic therapy, alitretinoin, is approved in Canada, the European Union, South Korea, and Israel.

Eczema 36

Eczema Safety Dermatology Therapy 36

Dermatology Times

APRIL 11, 2025

Panelists discuss how to identify suitable patients for JAK inhibitor therapy by evaluating disease severity, medical history, risk factors, and individual treatment goals while considering contraindications and safety considerations.

36

36

US Dermatologt Partners

JANUARY 13, 2025

Dermatology Partners Fairfax , Whether patients are dealing with persistent blackheads, painful cystic acne, or stubborn whiteheads, the temptation to pop or pick at acne is hard to resist. Schedule a Dermatologic Consultation Ready to say goodbye to acne breakouts? According to Dr. Kavya Desai of U.S. What Are Acne Extractions?

Extractions 41

Extractions Scarring Pores Chemical Peels 41

Dermatology Times

MARCH 14, 2025

Panelists discuss how JAK inhibitors demonstrate significant efficacy in treating atopic dermatitis while examining their safety profiles and optimal positioning within the therapeutic landscape.

Safety 36

Safety Dermatitis Therapy 36

The Dermatology Digest

FEBRUARY 18, 2025

I am looking forward to offering my patients this new treatment option which has the potential to address their most troublesome symptoms, says Curdin Conrad, MD, a Professor of Dermatology and Head of Policlinic and the center for psoriasis at Lausanne University Hospital in Switzerland, in a news release.

Dermatitis 36

Dermatitis Marketing Hospital Clinic 36

The Dermatology Digest

FEBRUARY 11, 2024

By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. Ireland PA, Jansson N, Spencer SKR. January 31, 2024. doi:10.1001/jamadermatol.2023.5509

Dermatology 74

Dermatology Safety Clinic Therapy 74

Dermatology Times

NOVEMBER 1, 2024

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Safety 57

Safety Therapy 57

The Dermatology Digest

FEBRUARY 10, 2025

Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. FDA Fast Tracks Nektar Therapeutics AD Candidate appeared first on The Dermatology Digest. ” The post AD Pipeline Watch: U.S.

Dermatitis 36

Dermatitis Therapy Office Safety 36

New Age Spa Institute

DECEMBER 18, 2024

Also known as NASI , this private beauty school in Des Plaines, IL offers training programs for professional licensing in esthetics, massage therapy, makeup, and more. Certifications are targeted programs designed to enhance your knowledge and skills in specific areas of esthetics, cosmetology, or massage therapy.

Medical 52

Medical Esthetics Legal Continuing Education 52

The Dermatology Digest

MARCH 9, 2025

Results from the pivotal ADEPT Phase 2/3 trial were shared in a late-breaking oral presentation at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

JUNE 5, 2024

The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. We believe that VYN201 has the potential to become a valuable and differentiated therapy for patients with vitiligo.

Safety 73

Safety Office Facials Therapy 73